WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003054020) HUMAN ANTIBODIES AGAINST HUMAN GLYCOPROTEIN VI AND THEIR USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/054020    International Application No.:    PCT/GB2002/005755
Publication Date: 03.07.2003 International Filing Date: 18.12.2002
IPC:
C07K 16/28 (2006.01)
Applicants: CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD [GB/GB]; The Old Schools, Trinity Lane, Cambridge, Cambridgeshire CB2 1TS (GB) (For All Designated States Except US).
SMETHURST, Peter, Alexander [GB/GB]; (GB) (For US Only).
OUWEHAND, Willem, Hendrik [NL/GB]; (GB) (For US Only).
FARNDALE, Richard, William [GB/GB]; (GB) (For US Only)
Inventors: SMETHURST, Peter, Alexander; (GB).
OUWEHAND, Willem, Hendrik; (GB).
FARNDALE, Richard, William; (GB)
Agent: WALTON, Seán, M.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB)
Priority Data:
0130543.2 20.12.2001 GB
Title (EN) HUMAN ANTIBODIES AGAINST HUMAN GLYCOPROTEIN VI AND THEIR USE
(FR) ANTICORPS HUMAINS AGISSANT CONTRE LA GLYCOPROTEINE VI ET LEUR UTILISATION
Abstract: front page image
(EN)Specific binding members directed to human glycoprotein VI (GPVI), in particular human antibodies, may employ the antibody VH and/or VL domain of the scFv fragment herein termed 10B12 or one or more complementarity determining regions (CDRs) of the 10B12 heavy chain variable (VH) and/or light chain variable (VL) domains, especially VH CDR3 in other antibody framework regions. Antibody molecules are provided with advantageous and unexpected properties, especially ability to inhibit collagen-induced platelet aggregation and the adhesion of platelets to Collagen-Related Peptide (CRP). Domain 1 of human GPVI is a primary target for the 10B12 antibody with these properties, and the epitope includes lysine 59.
(FR)Des éléments de liaison spécifiques dirigés contrer la glycoprotéine VI humaine (GPVI), en particulier des anticorps humains, peuvent utiliser le domaine anticorps VH et/ou VL du fragment scFv, dit 10B12, ou une ou plusieurs régions déterminantes complémentaires des domaines de 102B12 à variable à chaîne lourde (VH) et/ou à chaîne légère (VL), en particulier VH CDR3, dans d'autres régions structurales d'anticorps. L'invention concerne des molécules d'anticorps présentant des propriétés avantageuses et inattendues, en particulier l'aptitude à inhiber une agrégation des plaquettes induites par le collagène et l'adhésion de plaquettes à un peptide associé au collagène. Le domaine 1 de la glycoprotéine GPVI humaine constitue une cible principale de l'anticorps 10B12 doté de ces propriétés, et l'épitope comprend la lysine 59.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)